Skip to main content
. Author manuscript; available in PMC: 2017 Aug 10.
Published in final edited form as: Prostate. 2016 Feb 9;76(7):624–636. doi: 10.1002/pros.23155

Figure 1. Silencing cathelicidin-related antimicrobial peptide (CRAMP) expression in tumor cells in situ delays prostate cancer growth.

Figure 1

(A) Immunoblotting showing down-regulation of CRAMP following stable induction of shRNA construct targeting CRAMP gene in TRAMP-C1 cells. The levels of CRAMP were normalized to β-actin levels. Results are expressed as mean ± SD (n=3). **P < 0.01 (B) Down-regulated CRAMP was determined by real-time PCR in TRAMP-C1CRAMP-sh cells compared to TRAMP-C1 and TRAMP-C1scram-sh cells (mean ± SE) (n=3) ***P < 0.001 (C) C57BL/6 mice were subcutaneously implanted with TRAMP-C1, TRAMP-C1scram-sh or TRAMP-C1CRAMP-sh cells (5×105). Tumor volume is indicated as mm3 ± SE (n=10).